Pre-market Apr 2026: SHLTN.SW SHL Telemedicine (SIX) down 9.86%: watch earnings

The SHLTN.SW stock opened the Swiss pre-market under pressure after a 9.86% drop to CHF0.98, making it one of the top losers on the SIX this morning. The move follows thin trading of 5,453.00 shares and headlines focused on the company’s upcoming earnings on 22 Apr 2026. Investors should note the weak profitability metrics, including EPS -0.77 and PE -1.27, which help explain the sharp reaction ahead of the report. We use Meyka AI’s real-time tools to connect the fundamentals and technicals shaping this pre-market selloff.

Price action and drivers for SHLTN.SW stock

SHLTN.SW stock fell 9.86% in pre-market trade to CHF0.98 on low volume of 5,453.00 shares, underperforming its 50-day average of CHF1.07. The immediate driver is investor caution before the 22 Apr 2026 earnings announcement, which historically increases volatility in small-cap healthcare names. Market participants are also comparing SHL Telemedicine to sector peers where the Swiss healthcare group shows stronger profitability averages.

Fundamentals and valuation: why the selloff matters

SHL Telemedicine (SHLTN.SW) reports EPS -0.77 and a negative PE of -1.27, highlighting recent losses despite revenue per share of 3.53. The company trades at PB 0.52 and P/S 0.35, which suggests the market prices in low growth expectations but leaves a cushion versus book value. Working capital and cash ratios are weak with a current ratio 0.87, which raises financing and liquidity concerns for smaller-cap healthcare firms.

Technicals and market context for SHLTN.SW stock

Momentum indicators show downside pressure: RSI 39.73 and CCI -113.58 indicate the stock is near oversold territory while ADX 74.80 points to a strong trend. The 50-day average price is CHF1.07 and the 200-day average is CHF1.25, so the current CHF0.98 sits below both moving averages. Relative to the Healthcare sector on SIX, SHLTN.SW is underperforming the sector YTD metrics and average valuation multiples.

Meyka AI grade and model forecast for SHLTN.SW stock

Meyka AI rates SHLTN.SW with a score of 61.93 out of 100 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly price of CHF1.07 and a quarterly price of CHF0.89, reflecting mixed short-term momentum and event risk. Forecasts are model-based projections and not guarantees.

Catalysts, risks and trading considerations

The primary catalyst is the 22 Apr 2026 earnings announcement and any update on the Mayo Clinic collaboration or AI ECG development partnerships. Major risks include continued negative margins, low liquidity with average volume 18,196.00, and a fragile current ratio. Traders should size positions carefully and consider the stock’s volatility relative to small-cap healthcare peers on SIX.

Short-term outlook and price targets for SHLTN.SW stock

Analyst-style technicals imply near-term support at the year low CHF0.66 and resistance near the 50-day average CHF1.07. A conservative short-term price target based on Meyka scenario analysis is CHF1.07 (monthly) and a downside guard at CHF0.89 (quarterly). Position sizing should reflect market cap CHF16,030,376.00 and current liquidity constraints.

Final Thoughts

SHLTN.SW stock is a top pre-market loser on SIX after a 9.86% gap to CHF0.98, driven by low liquidity and an imminent earnings release on 22 Apr 2026. Fundamentals show EPS -0.77, PE -1.27, PB 0.52, and a current ratio 0.87, underlining profitability and short-term funding risks. Technicals show oversold momentum (RSI 39.73) within a strong downward trend (ADX 74.80). Meyka AI’s forecast model projects a monthly price of CHF1.07, implying +9.41% upside from the current CHF0.98, while the quarterly projection of CHF0.89 implies -9.00% downside. These model outputs reflect scenario-based paths and are not guarantees. Use small position sizes, watch the earnings release and any partnership updates, and consult multiple sources including the company site SHL Telemedicine and our internal stock page SHLTN.SW on Meyka. Meyka AI provides this AI-powered market analysis platform view to help frame risk and opportunity, not as investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.